61.2 Chronic Pain Syndromes & Chronic Daily Headaches

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

61.2 Chronic Pain Syndromes & Chronic Daily Headaches

Key Takeaways Explain This Topic AI

Chronic pain (>3-6 months) is a distinct neurobiological disease characterized by central sensitization, NMDA receptor activation, microglial neuroinflammation, and loss of descending monoaminergic inhibition; effective management requires an interdisciplinary biopsychosocial framework addressing sensory, emotional, and cognitive drivers.

The multimodal treatment paradigm for chronic pain prioritizes non-pharmacologic modalities (Cognitive Behavioral Therapy [CBT], Acceptance and Commitment Therapy [ACT], graded physical therapy) alongside non-opioid medications; long-term opioid therapy is avoided due to tolerance, dependence, functional decline, and opioid-induced hyperalgesia (OIH).

Chronic Daily Headache (CDH) encompasses headaches occurring on >=15 days/month for >3 months; Chronic Migraine requires >=15 headache days/month for >3 months with >=8 days meeting migraine criteria, managed with preventive therapies including topiramate, propranolol, amitriptyline, CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab), and OnabotulinumtoxinA injections.

Medication-Overuse Headache (MOH) arises in patients with pre-existing headache disorders who regularly consume acute treatments for >3 months (triptans, opioids, ergots, or combination analgesics on >=10 days/month, or simple analgesics on >=15 days/month); curative management demands immediate discontinuation or rapid taper of the overused agent, patient counseling regarding anticipated transient withdrawal rebound headache (2-10 days), transition to bridge therapy, and initiation of preventive migraine therapy.

Trigeminal Neuralgia (Tic Douloureux) is caused by neurovascular compression of the CN V root entry zone by the superior cerebellar artery, presenting with paroxysmal, lancinating, electric shock-like facial pain in the V2/V3 distribution triggered by innocuous cutaneous stimuli; carbamazepine is the first-line medication of choice, requiring baseline HLA-B*1502 screening in Asian descent, CBC and electrolyte monitoring, and high-resolution MRI to exclude multiple sclerosis or cerebellopontine angle tumors.

Last updated: September 2026

Neurobiology of Chronic Pain & The Biopsychosocial Model

Chronic pain is defined as pain that persists or recurs for longer than 3 to 6 months , extending beyond the anticipated healing time of damaged tissue. In the United States, chronic pain affects more than 20% of adults and represents a leading driver of disability, depression, and healthcare expenditure. Modern neurobiology conceptualizes chronic pain not as a prolonged symptom of ongoing tissue pathology, but as an independent, maladaptive neurobiological disease process characterized by central sensitization and neuroplastic reorganization.

Taxonomy of Pain Mechanisms

Nociceptive Pain : Arises from actual or threatened damage to non-neural tissue and is mediated by normally functioning nociceptive somatosensory receptors (e.g., osteoarthritis, acute trauma, rheumatoid synovitis).

Neuropathic Pain : Caused by a primary lesion or disease of the somatosensory nervous system (e.g., painful diabetic neuropathy, postherpetic neuralgia, radiculopathy, central post-stroke pain).

Nociplastic Pain : Pain arising from altered nociceptive processing despite no clear evidence of actual or threatened tissue damage or somatosensory system lesion (e.g., fibromyalgia, irritable bowel syndrome, non-specific chronic low back pain). CENTRAL SENSITIZATION: MOLECULAR & SYNAPTIC MECHANISMS

• Repetitive C-Fiber Stimulation ──> Sustained Presynaptic Release of Glutamate & Substance P
• │
• ▼
• Prolonged Depolarization of Dorsal Horn Neurons
• │
• ▼
• Magnesium (Mg2+) Plug Evicted from NMDA Receptors
• │
• ▼
• Massive Intracellular Calcium (Ca2+) Influx
• │
• ▼
• Activation of PKC, CaMKII & Intracellular Cascades
• │
• ▼
• Long-Term Potentiation (LTP) of Pain Synapses
• │
• ┌────────────────────────────────┴────────────────────────────────┐
• ▼ ▼
• ALLODYNIA (A-β Fibers) SECONDARY HYPERALGESIA
• Non-noxious tactile stimuli evoke pain Exaggerated pain response spreads widely
• due to novel synaptic cross-wiring beyond initial anatomical injury field
• Molecular Pathophysiology of Central Sensitization

Central sensitization represents an operational state of neuronal hyperexcitability within the dorsal horn of the spinal cord and higher cortical projection areas:

The 'Wind-Up' Phenomenon and NMDA Activation : Under physiological conditions, the N-methyl-D-aspartate (NMDA) receptor channel is tonically blocked by an extracellular magnesium ion ( Mg 2 + \text{Mg}^{2+} Mg 2 + ) . High-frequency, repetitive firing of unmyelinated primary afferent C-fibers releases sustained bursts of glutamate and substance P . These bind to postsynaptic AMPA and neurokinin-1 (NK-1) receptors, producing prolonged membrane depolarization that forcibly expels the Mg 2 + \text{Mg}^{2+} Mg 2 + plug. This allows unchecked calcium ( Ca 2 + \text{Ca}^{2+} Ca 2 + ) influx through NMDA channels, initiating intracellular cascades that activate protein kinase C (PKC) and calcium/calmodulin-dependent protein kinase II (CaMKII) .

Synaptic Plasticity & Receptive Field Expansion : Intracellular phosphorylation cascades insert additional AMPA receptors into the postsynaptic membrane (synaptic trafficking), establishing long-term potentiation (LTP) of nociceptive pathways. Consequently, dorsal horn wide dynamic range (WDR) neurons exhibit reduced activation thresholds, exaggerated firing frequencies, and expansion of receptive fields, leading to allodynia (pain elicited by non-painful stimuli) and hyperalgesia (exaggerated pain elicited by painful stimuli).

Glial Activation & Neuroinflammation : Spinal microglia and astrocytes become activated by fractalkine and ATP. They release pro-inflammatory mediators including IL-1β, TNF-α, and brain-derived neurotrophic factor (BDNF) . BDNF downregulates potassium-chloride cotransporters (KCC2) in dorsal horn neurons, reversing the physiological inhibitory action of GABA and glycine, causing disinhibition.

Failure of Descending Modulation : Endogenous descending analgesic pathways originating in the periaqueductal gray (PAG) and rostral ventromedial medulla (RVM) normally suppress spinal nociceptive transmission via norepinephrine and serotonin. In chronic pain states, these descending pathways become exhausted or switch to paradoxical descending facilitation.

Opioid-Induced Hyperalgesia (OIH) vs. Opioid Tolerance

A critical clinical challenge in chronic pain management is distinguishing opioid tolerance from opioid-induced hyperalgesia (OIH):

Opioid Tolerance : Characterized by a rightward shift of the dose-response curve; the patient requires escalating doses of opioids to achieve the same initial analgesic effect. Increasing the opioid dose temporarily restores analgesia.

Opioid-Induced Hyperalgesia (OIH) : A paradoxical state of neuroplastic nociceptive sensitization caused by exposure to opioids. Patients present with diffuse, ill-defined, spreading pain and generalized cutaneous allodynia that worsens as the opioid dose is escalated . Driven by dynorphin accumulation, activation of spinal NMDA receptors, and microglial release of neuroinflammatory mediators. Management requires cautious downward dose titration or rotation to an NMDA-receptor antagonist agent such as buprenorphine . OPIOID TOLERANCE VS. OPIOID-INDUCED HYPERALGESIA (OIH)

• Feature Opioid Tolerance Opioid-Induced Hyperalgesia (OIH)
• ══════════════════════════════════════════════════════════════════════════════════════════════════════════
• Mechanism Downregulation of μ-opioid receptors; NMDA receptor activation, dynorphin release,
• uncoupling of Gi/o protein signaling microglial neuroinflammation
• ──────────────────────────────────────────────────────────────────────────────────────────────────────
• Pain Distribution Anatomically consistent with original Diffuse, spreading beyond original site,
• pathological tissue injury generalized cutaneous allodynia
• ──────────────────────────────────────────────────────────────────────────────────────────────────────
• Effect of Dose Increase Temporary improvement in analgesia PARADOXICAL WORSENING of pain and allodynia
• ──────────────────────────────────────────────────────────────────────────────────────────────────────
• Management Strategy Rotate opioid or cautiously increase; GRADUAL OPIOID WEAN; rotate to buprenorphine;
• add multimodal non-opioid adjuvants add NMDA antagonists (ketamine)
• ══════════════════════════════════════════════════════════════════════════════════════════════════════════
• The Interdisciplinary Biopsychosocial Paradigm

The biopsychosocial framework recognizes that chronic pain is an emergent property of dynamic interactions between biological nociception, affective-emotional states, cognitive evaluations, and socio-environmental factors. Management requires an integrated, multimodal strategy:

Physical Rehabilitation : Graded exercise therapy, functional restoration, active stretching, and aquatic therapy to overcome kinesiophobia (fear of movement) and reverse musculoskeletal deconditioning.

Behavioral & Psychological Therapies :

Cognitive Behavioral Therapy (CBT) : Addresses pain catastrophizing, identifies cognitive distortions, and fosters active behavioral coping strategies.

Acceptance and Commitment Therapy (ACT) : Encourages psychological flexibility and commitment to values-based functional activities regardless of pain intensity.

Non-Opioid Pharmacotherapy : Tailored adjuvant agents (SNRIs, gabapentinoids, NSAIDs, topical agents) targeting specific neurochemical pathways.

Interventional Modalities : Fluoroscopically guided epidural steroid injections, radiofrequency ablation, or peripheral nerve stimulation as adjuncts to facilitate physical therapy.

Chronic Daily Headache (CDH) Spectrum

Chronic Daily Headache (CDH) is an umbrella clinical term applied to headache disorders occurring on ≥ 15 days per month for > 3 consecutive months \ge 15\text{ days per month for }>3\text{ consecutive months} ≥ 15 days per month for > 3 consecutive months . In primary care, the vast majority of CDH cases fall into three distinct clinical entities: Chronic Migraine, Chronic Tension-Type Headache, and Medication-Overuse Headache. DIAGNOSTIC CRITERIA & FEATURES OF CHRONIC DAILY HEADACHES

• Headache Subtype Frequency & Duration Clinical Phenotype & Associated Features
• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• Chronic Migraine >= 15 days/month for > 3 months; Unilateral or bilateral, pulsating/throbbing,
• on >= 8 days/month fulfills criteria moderate-to-severe, aggravated by routine physical

for migraine or responds to triptan activity; nausea, vomiting, photophobia, phonophobia.

• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• Chronic Tension-Type >= 15 days/month for > 3 months Bilateral, pressing/tightening ('band-like'),
• Headache (CTTH) (average >= 180 days/year) mild-to-moderate intensity; NO aggravation with
• activity; NO nausea/vomiting; at most one of

photophobia or phonophobia.

• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• Medication-Overuse >= 15 days/month in patient with Refractory, daily, holocephalic morning headache;
• Headache (MOH) pre-existing headache disorder; develops secondary to chronic overuse of acute abortive
• regular medication overuse for medications (triptans/opioids >= 10 days/month;

> 3 consecutive months simple analgesics >= 15 days/month).

• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• 1. Chronic Migraine

Pathophysiology : Chronic migraine evolves from episodic migraine via progressive sensitization of the trigeminovascular system . Sensory fibers from the ophthalmic division of the trigeminal nerve (CN V1) innervate the dural vasculature. Activation triggers perivascular release of vasoactive neuropeptides—predominantly Calcitonin Gene-Related Peptide (CGRP) , substance P, and neurokinin A. CGRP causes profound cerebral vasodilation, mast cell degranulation, plasma protein extravasation, and sterile neurogenic inflammation, driving central sensitization of second-order trigeminocervical neurons.

Preventive Pharmacotherapies :

Topiramate : 25 mg daily, titrated weekly by 25-50 mg to a target dose of 50 mg twice daily (100 mg/day) . Mechanism: blocks voltage-dependent sodium channels, potentiates GABA, and antagonizes AMPA/kainate receptors. High-yield side effects: paresthesias, weight loss, anorexia, cognitive slowing ('Dopamax' / word-finding difficulty), nephrolithiasis, metabolic acidosis via carbonic anhydrase inhibition, and teratogenicity (cleft lip/palate).

Beta-Blockers : Propranolol (80-240 mg/day extended-release) or Metoprolol (100-200 mg/day). First-line in young, healthy, or hypertensive patients. Contraindicated in moderate-to-severe asthma, bradycardia, or high-grade AV conduction block.

Tricyclic Antidepressants : Amitriptyline (10-75 mg at bedtime). Enhances descending monoaminergic inhibition. Excellent for patients with comorbid insomnia or chronic tension headache. Avoid in older adults per Beers criteria.

Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies :

Erenumab : Targets the canonical CGRP receptor (70-140 mg subcutaneously monthly).

Fremanezumab, Galcanezumab, Eptinezumab (IV): Target the CGRP ligand directly.

Well-tolerated, devoid of hepatorenal toxicity; common side effects include injection-site reactions and constipation (especially erenumab).

OnabotulinumtoxinA (Botox) Injections :

FDA-approved specifically for Chronic Migraine (ineffective for episodic migraine or tension headaches).

PREEMPT injection protocol: 155 Units distributed across 31 standardized anatomical injection sites covering 7 head and neck muscle groups (corrugator, procerus, frontalis, temporalis, occipitalis, cervical paraspinal, and trapezius) administered every 12 weeks .

2. Chronic Tension-Type Headache (CTTH)

Clinical Presentation : Bilateral, dull, aching, non-pulsatile pain with a pressing or tightening quality described as a 'vice' or 'tight band' around the cranium . Intensity is mild to moderate and does not prevent normal daily activities. Physical activity does not aggravate the headache. Nausea and vomiting are absent. Either photophobia or phonophobia may be present, but not both.

Management : The first-line evidence-based pharmacologic preventive agent is Amitriptyline (titrated from 10 mg to 50-75 mg at bedtime). Non-pharmacologic modalities include physical therapy targeting pericranial myofascial trigger points, electromyographic biofeedback, and stress reduction. Patients must be cautioned against frequent use of simple analgesics to prevent transition to medication-overuse headache.

3. Medication-Overuse Headache (MOH / Rebound Headache)

Medication-overuse headache is one of the most common and disabling conditions encountered in primary care headache medicine, affecting up to 1% to 2% of the general population and 30% to 50% of patients attending specialized headache clinics.

ICHD-3 Diagnostic Criteria :

Headache occurring on ≥ 15 days per month \ge 15\text{ days per month} ≥ 15 days per month in a patient with a pre-existing primary headache disorder.

Regular overuse of acute headache treatments for > 3 months >3\text{ months} > 3 months , defined as:

≥ 10 days per month \ge 10\text{ days per month} ≥ 10 days per month for ergotamines, triptans, opioids, or combination analgesics (e.g., butalbital-acetaminophen-caffeine [Fioricet], acetaminophen-aspirin-caffeine [Excedrin]).

≥ 15 days per month \ge 15\text{ days per month} ≥ 15 days per month for simple analgesics (acetaminophen, ibuprofen, naproxen).

Pathophysiology : Chronic, repetitive receptor binding by acute rescue agents induces cellular tolerance, downregulation of 5-HT1B/1D receptors, upregulation of pronociceptive CGRP pathways, and suppression of endogenous endocannabinoid and opioid inhibitory networks. The patient enters a self-perpetuating cycle where wearing off of the acute medication provokes a rebound withdrawal headache, prompting further medication consumption.

Clinical Management Protocol :

Patient Education : Validate the patient's suffering while clearly communicating the paradox: the medication used to abort the pain has become the primary mechanism sustaining the chronic headache.

Discontinuation of the Offending Agent : Immediate abrupt cessation is recommended for triptans, ergots, NSAIDs, and acetaminophen. In contrast, gradual outpatient tapering is mandatory for butalbital-containing compounds and opioids to avoid life-threatening withdrawal seizures or severe autonomic rebound.

Anticipate Withdrawal Rebound : Warn the patient that headaches will temporarily worsen for 2 to 10 days following discontinuation, frequently accompanied by nausea, insomnia, restlessness, and anxiety.

Bridge (Transition) Therapy : To alleviate withdrawal distress, prescribe a short-term bridge:

Oral Prednisone Taper : 60 mg daily for 3 days, tapered by 10-20 mg every 2 days over a 7- to 10-day course.

Scheduled Long-Acting NSAID : Naproxen 500 mg twice daily with gastroprotection (PPI) for 10 to 14 days (only if the overused agent was not an NSAID).

Antiemetics: Metoclopramide 10 mg or prochlorperazine 10 mg orally as needed.

Initiation of Preventive Therapy : Initiate effective evidence-based migraine prophylaxis (e.g., topiramate, CGRP monoclonal antibody, or OnabotulinumtoxinA) simultaneously with the withdrawal process rather than waiting for complete detoxification.

Trigeminal Neuralgia (Tic Douloureux)

Trigeminal neuralgia (TN) is an agonizing neuropathic disorder characterized by paroxysmal, unilateral facial pain. It has an incidence of approximately 4 to 13 per 100,000 person-years, with a slight female preponderance and peak onset after age 50. PATHOPHYSIOLOGY & ANATOMY OF TRIGEMINAL NEURALGIA

• Superior Cerebellar Artery (SCA) Aberrant Loop (80-90%)
• │
• ▼
• Pulsatile Mechanical Compression of CN V at Root Entry Zone (REZ) in Prepontine Cistern
• │
• ▼
• Focal Demyelination of Large Myelinated A-β Sensory Fibers
• │
• ▼
• Ephaptic Transmission ('Cross-Talk') to Adjacent Nociceptive A-δ & C Fibers
• │
• ▼
• Innocuous Tactile Stimulus (Light Touch, Shaving, Wind) ──> Sudden, Violent Lancinating Paroxysm
• Etiology & Pathophysiology

Classical Trigeminal Neuralgia : In over 80% to 90% of cases, classical TN is caused by mechanical neurovascular compression of the trigeminal sensory root at the Root Entry Zone (REZ) in the prepontine cistern. In the vast majority of cases, the compressing vessel is an aberrant or ectatic loop of the superior cerebellar artery (SCA) ; less commonly, the anterior inferior cerebellar artery (AICA) or a petrosal vein is implicated.

The Ephaptic 'Cross-Talk' Hypothesis : The REZ represents a transitional zone of anatomical vulnerability where peripheral Schwann cell myelination transitions to central oligodendroglial myelin. Chronic pulsatile vascular compression induces focal mechanical demyelination of heavily myelinated A-beta sensory fibers (which convey light touch). The close apposition of demyelinated membranes allows electrical charges to jump directly to neighboring unmyelinated and thinly myelinated A-delta and C nociceptive fibers via ephaptic transmission . Consequently, light tactile inputs directly ignite violent paroxysmal pain discharges.

Secondary Trigeminal Neuralgia : In approximately 10% to 15% of cases, the condition is secondary to structural pathology:

Multiple Sclerosis (MS) : Demyelinating plaque within the pontine trigeminal entry zone. Suspect in patients under 40 years of age or those presenting with bilateral facial pain .

Cerebellopontine Angle (CPA) Neoplasms : Meningioma, vestibular schwannoma, or epidermoid cyst compressing the trigeminal nerve root.

Clinical Manifestations

Paroxysmal, Excruciating Pain : Sudden, unilateral, lancinating, sharp, electrical shock-like, or stabbing pain lasting from a fraction of a second up to 2 minutes . Pain attacks often occur in clusters throughout the day.

Anatomical Distribution : Pain is strictly restricted to one or more sensory divisions of the trigeminal nerve (CN V). The maxillary division (V2) and mandibular division (V3) are involved in over 90% of cases (frequently together). The ophthalmic division (V1) is affected in < 5 % <5\% < 5% of cases.

Cutaneous Trigger Zones : Agonizing paroxysms are provoked by trivial, non-noxious mechanical stimulation of specific trigger zones on the face or oral cavity: light touch, brushing teeth, chewing, talking, shaving, washing the face, smiling, or a cold breeze .

Refractory Period : Characteristically, each paroxysm is followed by a brief refractory interval lasting seconds to minutes during which mechanical stimulation cannot provoke another attack.

Physical Examination : In classical trigeminal neuralgia, the cranial nerve examination is COMPLETELY NORMAL . Objective sensory loss (e.g., facial hypesthesia, loss of corneal reflex) or motor weakness of the muscles of mastication is an alarming red flag indicating secondary structural pathology (tumor or demyelinating disease).

Diagnostic Neuroimaging

Every patient with suspected trigeminal neuralgia must undergo high-resolution Magnetic Resonance Imaging (MRI) of the Brain with thin-slice 3D construct sequences (e.g., CISS or FIESTA) with and without IV gadolinium contrast. MRI evaluates for neurovascular compression at the root entry zone and rules out multiple sclerosis demyelinating plaques and CPA tumors.

Pharmacotherapy of Trigeminal Neuralgia PHARMACOTHERAPY OF TRIGEMINAL NEURALGIA

Agent Dosage & Titration Clinical Pearls & Mechanism Monitoring & Toxicities

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════

Carbamazepine Start 100-200 mg BID; titrate by GOLD STANDARD FIRST-LINE; CBC (aplastic anemia, agranulocytosis),

(First-Line) 200 mg every 2-3 days to target blocks voltage-gated Na+ electrolytes (SIADH/hyponatremia), LFTs.

600-1200 mg/day (max: 1200 mg/day) channels; >80% initial relief HLA-B*1502 screening in Asian descent!

• ───────────────────────────────────────────────────────────────────────────────────────────────────────────
• Oxcarbazepine Start 150-300 mg BID; titrate First-line alternative; Electrolytes (higher incidence of
• (First-Line) by 300 mg every 3 days to target equal efficacy, better hyponatremia than carbamazepine);

1200-1800 mg/day in divided doses tolerability, fewer drug DIs somnolence, dizziness, ataxia.

• ───────────────────────────────────────────────────────────────────────────────────────────────────────────
• Baclofen Start 5-10 mg TID; titrate to Second-line add-on agent; Sedation, muscle weakness, confusion;
• (Add-on) target 40-80 mg/day GABA-B receptor agonist; avoid abrupt withdrawal (seizures,

synergistic with Na+ blockers hallucinations, delirium).

• ───────────────────────────────────────────────────────────────────────────────────────────────────────────
• Lamotrigine Start 25 mg daily; slow titration Second-line add-on agent; Risk of severe cutaneous eruption /
• (Add-on) over 6-8 weeks to 200-400 mg/day blocks Na+ channels and Stevens-Johnson syndrome with

inhibits glutamate release rapid titration.

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════

Carbamazepine : First-line gold standard therapy, providing prompt relief in > 80 % >80\% > 80% of patients. Mechanism: stabilizes the inactivated state of voltage-gated sodium channels, curbing high-frequency repetitive discharges.

Adverse Effects : Somnolence, dizziness, diplopia, ataxia, nausea, hyponatremia due to an SIADH-like effect, elevated transaminases, leukopenia, and rare but catastrophic aplastic anemia or agranulocytosis .

Pharmacogenomic Screening : The US FDA mandates screening for the HLA-B*1502 allele prior to starting carbamazepine in patients of Asian ancestry (Han Chinese, Taiwanese, Thai, Malaysian, Filipino, Indian). The HLA-B*1502 allele carries an extreme hazard ratio ( > 100 >100 > 100 ) for developing life-threatening Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) .

Laboratory Monitoring : Baseline CBC, electrolytes, and hepatic transaminases, repeated at 2 to 4 weeks, 3 months, and periodically thereafter.

Oxcarbazepine : Keto-derivative of carbamazepine acting as a prodrug for 10-monohydroxy metabolite (MHD). Equal clinical efficacy to carbamazepine with lower hepatic enzyme induction and fewer drug-drug interactions, but carries a higher risk of clinically significant hyponatremia .

Surgical Interventions for Trigeminal Neuralgia

Surgical consultation is indicated for patients with medically refractory pain, breakthrough paroxysms, or intolerable drug toxicities:

Microvascular Decompression (MVD / Jannetta Procedure) :

Suboccipital retrosigmoid craniotomy to visualize the trigeminal root entry zone in the posterior fossa. The offending compressing artery (usually the SCA) is dissected away from the nerve and an inert Teflon felt sponge is interpositioned between the vessel and the nerve root.

Definitive Treatment : Achieves the highest long-term pain-free remission rate ( > 70 − 80 % >70-80\% > 70 − 80% at 5 to 10 years) without producing facial numbness or sensory loss. Operative mortality is < 0.5 % <0.5\% < 0.5% ; risks include hearing loss (CN VIII injury), CSF leak, and cerebellar stroke.

Percutaneous Rhizotomy Procedures :

Radiofrequency thermocoagulation, glycerol rhizolysis, or percutaneous balloon microcompression performed via a needle inserted through the cheek into the foramen ovale to selectively injure trigeminal pain fibers in Meckel's cave. Effective alternative for older or frail patients unable to tolerate open craniotomy; trades pain relief for varying degrees of facial hypesthesia, dysesthesias, or corneal anesthesia (loss of corneal blink reflex with risk of neurotrophic keratitis).

Stereotactic Radiosurgery (Gamma Knife) :

Highly focused, single-fraction ionizing radiation delivered to the trigeminal root entry zone. Non-invasive, outpatient procedure suitable for high-risk surgical candidates. Pain relief is delayed, taking 4 to 8 weeks to manifest.

Loading diagram... Clinical Management of Chronic Daily Headaches and Trigeminal Neuralgia